Patni, Nivedita
Garg, Abhimanyu
Article History
First Online: 4 August 2015
Competing interests
: A.G. co-holds a patent regarding the use of leptin for treating human lipoatrophy and the method of determining predisposition to this treatment but receives no financial compensation. A.G. has received research grants from Aegerion, Astra-Zeneca, Bristol-Myers-Squibb and Pfizer and is a consultant for Amgen, Back Bay Life Sciences, Biomarin Pharmaceuticals, BioMedical Insights, Clearview Healthcare, Eli Lilly, Engage Health, Gerson Lehrman Group, Health Advances, Ipsen Pharmaceuticals, Intellisphere, Medscape and Tekmira. A.G. is also an advisory board member for AstraZeneca. N.P. declares no competing interests.